Clinical Response and Remission in Patients With Severe Asthma Treated With Biologic Therapies

Susanne Hansen, Marianne Baastrup Søndergaard, Anna von Bülow, Anne Sofie Bjerrum, Johannes Schmid, Linda M. Rasmussen, Claus R. Johnsen, Truls Ingebrigtsen, Kjell Erik Julius Håkansson, Sofie Lock Johansson, Maria Bisgaard, Karin Dahl Assing, Ole Hilberg, Charlotte Ulrik, Celeste Porsbjerg*

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

12 Downloads (Pure)

Abstract

Background: The development of novel targeted biologic therapies for severe asthma has provided an opportunity to consider remission as a new treatment goal. Research Question: How many patients with severe asthma treated with biologic therapy achieve clinical remission, and what predicts response to treatment? Study Design and Methods: The Danish Severe Asthma Register is a nationwide cohort including all adult patients receiving biologic therapy for severe asthma in Denmark. This observational cohort study defined “clinical response” to treatment following 12 months as a ≥ 50% reduction in exacerbations and/or a ≥ 50% reduction in maintenance oral corticosteroid dose, if required. “Clinical remission” was defined by cessation of exacerbations and maintenance oral corticosteroids, as well as a normalization of lung function (FEV1 > 80%) and a six-question Asthma Control Questionnaire score ≤ 1.5 following 12 months of treatment. Results: Following 12 months of treatment, 104 (21%) of 501 biologic-naive patients had no response to treatment, and 397 (79%) had a clinical response. Among the latter, 97 (24%) fulfilled the study criteria of clinical remission, corresponding to 19% of the entire population. Remission was predicted by shorter duration of disease and lower BMI in the entire population of patients treated with biologic therapy. Interpretation: Clinical response was achieved in most adult patients initiating biologic therapy, and clinical remission was observed in 19% of the patients following 12 months of treatment. Further studies are required to assess the long-term outcome of achieving clinical remission with biologic therapy.

Original languageEnglish
JournalChest
Volume165
Issue number2
Pages (from-to)253-266
ISSN0012-3692
DOIs
Publication statusPublished - Feb 2024

Bibliographical note

Publisher Copyright:
© 2023 The Author(s)

Keywords

  • biologics
  • epidemiology
  • remission
  • severe asthma

Fingerprint

Dive into the research topics of 'Clinical Response and Remission in Patients With Severe Asthma Treated With Biologic Therapies'. Together they form a unique fingerprint.

Cite this